Eli Lilly and Company (LLY)
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
One key disease-prevention market is drawing closer to being within reach.
Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock
The odds of its new drug getting established in the U.K. are now much lower.
What You Need To Know Ahead of Eli Lilly Earnings
As pharmaceutical giant Eli Lilly (LLY) plans to report third-quarter earnings Wednesday morning, analysts are focused on the production and sales of Mounjaro and Zepbound—two popular weight-loss drugs that have boosted the company's results.
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
Eli Lilly stock (NYSE: LLY) will report its Q3 results on Wednesday, October 30. The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates.
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't.
Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News
Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.
Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter.
2 Soaring Growth Stocks That Are Still Worth Buying
These two companies -- leaders in their industries -- look unstoppable.
Lilly (LLY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top -and-bottom-line estimates for Lilly (LLY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly Is Putting On Some Weight As Earnings Near
Eli Lilly and Company has shown rapid growth, driven by its weight loss drugs Mounjaro and Zepbound, with significant revenue increases. Despite impressive growth, I maintain a 'hold' rating due to the stock's high valuation, which I find prohibitive. Analysts expect strong Q3 2024 results, with projected revenue of $12.11 billion and adjusted net income of $1.31 billion.
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
